Multiple Mutations Modulate the Function of Dihydrofolate Reductase in Trimethoprim-Resistant Streptococcus pneumoniae
Open Access
- 1 April 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (4) , 1104-1108
- https://doi.org/10.1128/aac.45.4.1104-1108.2001
Abstract
Trimethoprim resistance in Streptococcus pneumoniaecan be conferred by a single amino acid substitution (I100-L) in dihydrofolate reductase (DHFR), but resistant clinical isolates usually carry multiple DHFR mutations. DHFR genes from five trimethoprim-resistant isolates from the United Kingdom were compared to susceptible isolates and used to transform a susceptible control strain (CP1015). All trimethoprim-resistant isolates and transformants contained the I100-L mutation. The properties of DHFRs from transformants with different combinations of mutations were compared. In a transformant with only the I100-L mutation (R12/T2) and a D92-A mutation also found in the DHFRs of susceptible isolates, the enzyme was much more resistant to trimethoprim inhibition (50% inhibitory concentration [IC50], 4.2 μM) than was the DHFR from strain CP1015 (IC50, 0.09 μM). However,K m values indicated a lower affinity for the enzyme's natural substrates (K m for dihydrofolate [DHF], 3.1 μM for CP1015 and 27.5 μM for R12/T2) and a twofold decrease in the specificity constant. In transformants with additional mutations in the C-terminal portion of the enzyme, K mvalues for DHF were reduced (9.2 to 15.2 μM), indicating compensation for the lower affinity generated by I100-L. Additional mutations in the N-terminal portion of the enzyme were associated with up to threefold-increased resistance to trimethoprim (IC50 of up to 13.7 μM). It is postulated that carriage of the mutation M53-I—which, like I100-L, corresponds to a trimethoprim binding site in the Escherichia coli DHFR—is responsible for this increase. This study demonstrates that although the I100-L mutation alone may give rise to trimethoprim resistance, additional mutations serve to enhance resistance and modulate the effects of existing mutations on the affinity of DHFR for its natural substrates.Keywords
This publication has 14 references indexed in Scilit:
- The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 2000
- A Conservative Amino Acid Mutation in the Chromosome‐Encoded Dihydrofolate Reductase Confers Trimethoprim Resistance inStreptococcus pneumoniaeThe Journal of Infectious Diseases, 1998
- Molecular Epidemiology of Drug-Resistant Pneumococci: Toward an International ApproachMicrobial Drug Resistance, 1997
- Antimicrobial susceptibility of community-acquired bacterial lower respiratory tract pathogensJournal of Antimicrobial Chemotherapy, 1996
- Cloning and characterization of a novel, plasmid-encoded trimethoprim-resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313Antimicrobial Agents and Chemotherapy, 1995
- Saturation mutagenesis at dihydrofolate reductase codons 22 and 31 A variety of amino acid substitutions conferring methotrexate resistanceBiochemical Pharmacology, 1994
- Pneumococcal resistance to antibioticsClinical Microbiology Reviews, 1990
- Dihydrofolate reductase hysteresis and its effect on inhibitor binding analysesBiochemistry, 1981
- Escherichia coli dihydrofolate reductase: isolation and characterization of two isozymesBiochemistry, 1977
- CO-TRIMOXAZOLE-RESISTANT PNEUMOCOCCIThe Lancet, 1972